Interações medicamentosas potenciais no setor de oncopediatria em um Hospital Universitário.

Abstract

In the face of all the progress, the second cause of death among children and adolescents 1-19 years in Brazil is because of to cancer. The child cancer is quite different from that affect adults as it has better response to chemotherapy, but in return have different places of histological origin, clinical behavior and primary sites. Cancer patients are usually polymedicated, and the occurrence of common drug interactions in this population. Thus, the study aimed to carry out the study of potential drug interactions in the Oncopediatrics sector of University Hospital Alcides Carneiro in Campina Grande-PB, being a cross-sectional retrospective study, whose data source was a prescription drug. Its population consisted of all patients admitted to the sector in the period from January to June 2016. The prescription drugs were evaluated for the possibility of drug interactions with the aid of Micromedex Solutions® database. During the study period, they were evaluated 75 treatments, corresponding to 22 patients. Among the patients, remained majority males, with a predominant age group 1-5 years. As for the diagnosis of cancer, hematologic were majority; the central causes for the justification of hospitalization said to chemotherapy continuous administration. Of the drugs analyzed during the 6-month study, there was the presence of 208 potential drug interactions, and 133 between antineoplastic/antineoplastic and antineoplastic/ adjuvants ranked among the largest and moderate mostly. This study showed that the prescription medicines in oncology requires a careful evaluation of the prescriber, the combined treatment of various drugs, can create risks that compromise the overall picture of the patient. Thus, it reinforces the need for multidisciplinary interaction, and urges the need for implementation of clinical pharmacy in hospitals, which would facilitate further study of drug use, optimizing service and plotting new treatment strategies.